MedTrace Logo

Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

NCT07770828 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2026-08-19

No results posted yet for this study

Summary

This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm

Conditions

Interventions

BIOLOGICAL

OCU410

Subretinal Injection

Sponsors & Collaborators

Principal Investigators

  • Mohamed Genead, MD · Ocugen., Inc.

  • Jennifer Henrick · Ocugen., Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-11
Primary Completion
2028-07-30
Completion
2031-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07770828 on ClinicalTrials.gov